A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway

Simply Wall St.

Feb 25

AdvertisementWhy ORIC Pharmaceuticals stock is back on investors’ radar ORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614703962"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614703962\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614703962?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-25 23:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614703962","market":"hk","top_or_hot":-1,"title":"A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy ORIC Pharmaceuticals stock is back on investors’ radar ORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 23:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy ORIC Pharmaceuticals stock is back on investors’ radar ORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORIC","symbol_name":"Oric Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b","article_id":"2614703962","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614703962","pubTimestamp":1772033712,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why ORIC Pharmaceuticals stock is back on investors’ radar\nORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new funding that management expects will cover operations into the second half of 2028.\nSee our latest analysis for ORIC Pharmaceuticals.\nThe recent Phase 1b readouts, extended cash runway into late 2028 and new equity programs have all landed alongside a strong 64.26% year to date share price return. The 3 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORIC":"Oric Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"1b期业绩和现金跑道延长后ORIC Pharmaceuticals(ORIC)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORIC":1.5},"content_text":"AdvertisementWhy ORIC Pharmaceuticals stock is back on investors’ radar ORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new funding that management expects will cover operations into the second half of 2028. See our latest analysis for ORIC Pharmaceuticals. The recent Phase 1b readouts, extended cash runway into late 2028 and new equity programs have all landed alongside a strong 64.26% year to date share price return. The 3 year total shareholder return of 205% contrasts with a 5 year total shareholder return of 62.97%, suggesting momentum has gathered pace more recently. If ORIC’s oncology progress has caught your attention, this could be a good moment to look across the sector with our screener of 28 healthcare AI stocks identified by Simply Wall St. With ORIC still loss making but trading at US$13.42, around 42% below the average analyst price target of US$21.23, investors may ask whether this is an underappreciated oncology story or whether the market is already pricing in future growth. Preferred Price to Book of 3.9x: Is it justified? On a P/B of 3.9x, ORIC sits between what its direct peers are trading on and the broader biotech group. This sets up a mixed read on valuation at the last close of $13.42. The P/B multiple compares a company’s market value to its net assets on the balance sheet. It is often used for pre revenue or loss making biopharma names where earnings based metrics are less useful. For ORIC, the data suggests two things at once: the shares are described as good value versus a peer average P/B of 19.4x, yet as expensive against the wider US biotech industry where the average P/B sits at 2.7x. That split can matter for how you view the story. Compared to close peers, the market is assigning a much lower multiple to ORIC’s asset base. This may reflect its lack of meaningful revenue so far, ongoing losses of $129.47m and analyst expectations that earnings are forecast to decline by an average of 3.3% per year over the next 3 years with no revenue expected next year. Versus the broader biotech industry, though, a 3.9x P/B is higher than the 2.7x average, suggesting investors are already ascribing a premium relative to many smaller or earlier stage names. With no reliable fair ratio or discounted cash flow estimate available, this leaves the P/B comparison as the main reference point investors have to judge how the market is currently weighing ORIC’s balance sheet and pipeline against an extended loss making profile and volatile share price over the past 3 months. See what the numbers say about this price — find out in our valuation breakdown. Result: Price to Book of 3.9x (ABOUT RIGHT) However, you are still looking at a company with no revenue, a US$129.47m annual loss, and clinical trials that may not deliver the outcomes investors currently expect. Find out about the key risks to this ORIC Pharmaceuticals narrative. Next Steps If this all feels finely balanced, it is worth checking the numbers yourself and deciding quickly where you stand. You can start by reviewing the 5 important warning signs. Looking for more investment ideas? If ORIC has sharpened your focus, do not stop here. Use the tools available to you and keep broadening your watchlist with fresh opportunities.  Spot potential bargains early by checking companies our screener flags as screener containing 23 high quality undiscovered gems before they appear on everyone else’s radar. Strengthen your core holdings by reviewing stocks in the solid balance sheet and fundamentals stocks screener (40 results) that pair sturdier finances with clearer fundamentals. Target income opportunities by scanning the 16 dividend fortresses for companies offering higher yields with an emphasis on stability.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}